• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

viral vectors

Redbrick building with Sarepta name and logo
Favicon Fierce Pharma

2nd patient dies after Sarepta's DMD gene therapy Elevidys

Sarepta has suspended giving Elevidys to non-ambulatory DMD patients in the commercial setting while it seeks FDA approval of a risk mitigation plan.
Angus Liu Jun 16, 2025 10:58am
gene therapy AAV adeno-associated viruses

Neurogene details death in Rett syndrome gene therapy trial

May 16, 2025 3:00pm
AAV virus capsid

Vertex discontinues AAV research for gene therapies

May 2, 2025 6:22pm
Black phone dangling by cord in phonebooth

Ring lays off nearly half of staff, CEO to exit in new year

Dec 18, 2024 2:31pm
hepatitis B virus

GSK axes hepatitis B vaccine trial after missing efficacy goal

Dec 4, 2024 5:15am
A rainbow-colored viral vector containing a gene therapy against a background of rainbow-colored double-helix DNA

Ring's 'new class of viral vector' is re-dosable in primates

May 8, 2024 5:05pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings